Insulin-releasing and metabolic effects of small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline.

Nigel Irwin, Peter Flatt, Steven Patterson, BD Green

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Much recent attention has focused on the GLP-1 receptor as a potential target for antidiabetic drugs. Enzyme resistant GLP-1 mimetics such as exenatide are now employed for the treatment of type 2 diabetes, but must be administered by injection. The present study has examined and compared the in vitro and in vivo metabolic actions of a small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline (DMB), with native GLP-1, exenatide and liraglutide. DMB significantly stimulated in vitro insulin secretion from BRIN-BD11 cells but with decreased molar potency compared to native GLP-1 or related mimetics. Administration of DMB in combination with glucose to mice significantly (P
LanguageEnglish
Pages268-273
JournalEuropean Journal of Pharmacology
Volume628
Issue number1-3
DOIs
Publication statusPublished - 25 Feb 2010

Fingerprint

Glucagon-Like Peptide 1
Insulin
Hypoglycemic Agents
Type 2 Diabetes Mellitus
Glucose
Injections
Enzymes
Glucagon-Like Peptide-1 Receptor
3-(tert-butylamino)-6,7-dichloro-2-(methylsulfonyl)quinoxaline
exenatide
In Vitro Techniques
Therapeutics

Cite this

@article{70d5990523d8411791523d1e28471f98,
title = "Insulin-releasing and metabolic effects of small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline.",
abstract = "Much recent attention has focused on the GLP-1 receptor as a potential target for antidiabetic drugs. Enzyme resistant GLP-1 mimetics such as exenatide are now employed for the treatment of type 2 diabetes, but must be administered by injection. The present study has examined and compared the in vitro and in vivo metabolic actions of a small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline (DMB), with native GLP-1, exenatide and liraglutide. DMB significantly stimulated in vitro insulin secretion from BRIN-BD11 cells but with decreased molar potency compared to native GLP-1 or related mimetics. Administration of DMB in combination with glucose to mice significantly (P",
author = "Nigel Irwin and Peter Flatt and Steven Patterson and BD Green",
year = "2010",
month = "2",
day = "25",
doi = "10.1016/j.ejphar.2009.11.022",
language = "English",
volume = "628",
pages = "268--273",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-3",

}

Insulin-releasing and metabolic effects of small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline. / Irwin, Nigel; Flatt, Peter; Patterson, Steven; Green, BD.

In: European Journal of Pharmacology, Vol. 628, No. 1-3, 25.02.2010, p. 268-273.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Insulin-releasing and metabolic effects of small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline.

AU - Irwin, Nigel

AU - Flatt, Peter

AU - Patterson, Steven

AU - Green, BD

PY - 2010/2/25

Y1 - 2010/2/25

N2 - Much recent attention has focused on the GLP-1 receptor as a potential target for antidiabetic drugs. Enzyme resistant GLP-1 mimetics such as exenatide are now employed for the treatment of type 2 diabetes, but must be administered by injection. The present study has examined and compared the in vitro and in vivo metabolic actions of a small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline (DMB), with native GLP-1, exenatide and liraglutide. DMB significantly stimulated in vitro insulin secretion from BRIN-BD11 cells but with decreased molar potency compared to native GLP-1 or related mimetics. Administration of DMB in combination with glucose to mice significantly (P

AB - Much recent attention has focused on the GLP-1 receptor as a potential target for antidiabetic drugs. Enzyme resistant GLP-1 mimetics such as exenatide are now employed for the treatment of type 2 diabetes, but must be administered by injection. The present study has examined and compared the in vitro and in vivo metabolic actions of a small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline (DMB), with native GLP-1, exenatide and liraglutide. DMB significantly stimulated in vitro insulin secretion from BRIN-BD11 cells but with decreased molar potency compared to native GLP-1 or related mimetics. Administration of DMB in combination with glucose to mice significantly (P

U2 - 10.1016/j.ejphar.2009.11.022

DO - 10.1016/j.ejphar.2009.11.022

M3 - Article

VL - 628

SP - 268

EP - 273

JO - European Journal of Pharmacology

T2 - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-3

ER -